Targeting cancer using fragment based drug discovery

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 1, 2012, Pages 40-48

  Turnbull, Andrew P ^a   Boyd, Susan M ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b IOTA Pharmaceuticals Ltd   (United States)

Author keywords

Cancer; Drug discovery; Fragment screening; Ligand efficiency

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AURORA KINASE INHIBITOR; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 5; ENZYME INHIBITOR; HEAT SHOCK PROTEIN 90; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MEXILETINE; NAVITOCLAX; PEPTIDYLPROLYL ISOMERASE PIN1; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 INHIBITOR; PLX 4720; PROTEIN BCL 2; PROTEIN KINASE B; SAR 011797; UNCLASSIFIED DRUG; VEMURAFENIB;

AFFINITY CHROMATOGRAPHY; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DIFFERENTIAL SCANNING FLUORIMETRY; DRUG DESIGN; DRUG INDUSTRY; DRUG TARGETING; FRAGMENT BASED DRUG DISCOVERY; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; THERMAL SHIFT ASSAY; VALIDATION PROCESS; X RAY CRYSTALLOGRAPHY;

EID: 84855282457     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012798764660     Document Type: Article

References (67)

1. Card, G.L.; Blasdel, L.; England, B.P.; Zhang, C.; Suzuki, Y.; Gillette, S.; Fong, D.; Ibrahim, P.N.; Artis, D.R.; Bollag, G.; Milburn, M.V.; Kim, S-H.; Schlessinger, J.; Zhang, K.Y.J. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat. Biotechnol., 2005, 23, 201-207.
2. Petros, A.M.; Dinges, J.; Augeri, D.J.; Baumeister, S.A.; Betebenner, D.A.; Bures, M. G.; Elmore, S. W.; Hajduk, P.J.; Joseph, M.K.; Landis, S.K.; Nettesheim, D.G.; Rosenberg, S.H.; Shen, W.; Thomas, S.; Wang, X.; Zanze, I.; Zhang, H.; Fesik, S.W. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J. Med. Chem., 2006, 49, 656-663.
3. Murray, C.W.; Blundell, T.L. Structural biology in fragment-based drug design. Curr. Opin. Struct. Biol., 2010, 20, 497-507.
4. Coyne, A.G.; Scott, D.E.; Abell, C. Drugging challenging targets using fragment-based approaches. Curr. Opin. Chem. Biol., 2010, 14, 299-307.
5. Schulz, M.N.; Hubbard, R.E. Recent progress in fragment-based lead discovery. Curr Opin Pharmacol., 2009 9, 615-621.
6. Fink, T.; Bruggesser, H.; Reymond, J.L. Virtual exploration of the small-molecule chemical universe below 160 daltons. Angew. Chem., Int. Ed., 2005, 44, 1504-1508.
7. Bohacek, R.S.; McMartin, C.; Guida, W.C. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev., 1996, 16, 3-50.
8. Hopkins, A.L.; Groom, C.R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today, 2004, 9, 430-431.
9. Kuntz, I.D.; Chen, K.; Sharp, K.A.; Kollman, P.A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. USA, 1999, 96, 9997-10002.
10. Carr, R.A.; Congreve, M.; Murray, C.W.; Rees, D.C. Fragmentbased lead discovery: leads by design. Drug Discov. Today, 2005, 10, 987-92.
11. Hann, M.M.; Leach, A.R.; Harper, G. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery. J. Chem. Inf. Model., 2001, 41, 856-864.
12. Jacoby, E.; Davies, J.; Blommers, M.J. Design of small molecule libraries for NMR screening and other applications in drug discovery. Curr. Top. Med. Chem., 2003, 3, 11-23.
13. Hubbard, R.E.; Chen, I.; Davis, B. Informatics and modelling challenges in fragment-based drug discovery. Curr. Opin. Drug Discov. Dev., 2007, 10, 289-297.
14. Siegal, G.; Ab, E.; Schultz, J. Integration of fragment screening and library design. Drug Discov. Today, 2007, 12, 1032-1039.
15. Boyd, S. M.; de Kloe, G. E. Fragment Library Design: Efficiently Hunting Drugs in Chemical Space, Drug Discov. Today: Technologies, 2010, 7(3), 173-180; doi:10.1016
16. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A 'Rule of Three' for fragment-based lead discovery? Drug Discov. Today, 2003, 8, 876-877.
17. Akritopoulou-Zanze, I.; Hajduk, P.J. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov. Today, 2009, 14, 291-297
18. Gianti, E.; Sartori, L. Identification and selection of "privileged fragments" suitable for primary screening. J. Chem. Inform. Model, 2008, 48, 2129-2139.
19. Affinity capillary electrophoresis method for assessing a biological interaction of a ligand/receptor pair such as G protein coupled receptor and its targets as well as for drug screening. Patent pending, PCT/GB2010/051574.
20. Duong-Thi, M-D.; Meiby, E.; Bergström, M.; Fex, T.; Isaksson, R.; Ohlson, S. Weak affinity chromatography as a new approach for fragment screening in drug discovery. Anal Biochem., 2011, 414, 138-146.
21. Shuker, S.B.; Hajduk, P.J.; Meadows, R.P.; Fresik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science, 1996, 274, 1531-1534.
22. Hajduk, P.J. SAR by NMR: putting the pieces together. Mol. Interv., 2006, 6, 266-272.
23. Klages, J.; Coles, M.; Kessler, H. NMR-based screening: a powerful tool in fragment-based drug discovery. Mol. Biosyst., 2006, 2, 319-331.
24. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed., 1999, 38, 1784-1788.
25. Dalvit, C.; Pevarello, P.; Tatò, M.; Veronesi, M.; Vulpetti, A.; Sundström, M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR, 2000, 18, 65-68.
26. Siriwardena, A.H.; Tian, F.; Noble, S.; Prestegard, J.H. A straightforward NMR-spectroscopy-based method for rapid library screening. Angew. Chem., Int. Ed. Engl., 2002, 41, 3454-3457.
27. Vanwetswinkel, S.; Heetebrij, R.J.; van Duynhoven, J.; Hollander, J.G.; Filippov, D.V.; Hajduk, P.J.; Siegal, G. TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery. Chem. Biol., 2005, 12, 207-216.
28. Filmore, D. It's a GPCR world. Modern Drug Discov., 2004, 7, 24-28.
29. Swann, S.L.; Song, D.; Sun, C.; Hajduk, P.J.; Petros, A.M. Labeled ligand displacement: extending NMR-based screening of protein targets. ACS Med. Chem. Lett., 2010, 1, 295-299.
30. Carr, R.; Jhoti, H. Structure-based screening of low-affinity compounds. Drug Discov. Today, 2002, 7, 522-527.
31. Verlinde, C.L.M.J.; Rudenko, G.; Hol, W.G.J.; In search of new lead compounds for trypanosomiasis drug design: a protein structure- based linked-fragments approach. J. Comput. Aided Mol. Des., 1992, 6, 131-147.
32. Verlinde, C.L.M.J.; Kim, H.; Bernstein, B.E.; Mande, S.C.; Hol, W.G.J.; Anti-trypanosomiasis drug development based on structures of glycolytic enzymes. In 'Structure-based drug design', Ed. Veerapandian. Marcel Dekker, NY, 1997, 365-394.
33. Manjasetty, B.A.; Turnbull, A.P.; Panjikar, S.; Büssow, K.; Chance, M.R. Automated technologies and novel techniques to accelerate protein crystallography for structural genomics. Proteomics, 2008, 8, 612-625.
34. Blundell, T.L.; Abell, C.; Cleasby, A.; Hartshorn, M.J.; Tickle, I.J.; Parasini, E.; Jhoti, H. High-throughput X-ray crystallography for drug discovery. In Drug design: special publication; Flower, D. R., Ed.; Royal Society of Chemistry: Cambridge, UK, 2002, 53-59.
35. Muchmore, S. W.; Olson, J.; Jones, R.; Pan, J.; Blum, M.; Greer, J.; Merrick, S. M.; Magdalinos, P.; Nienaber, V. L. Automated crystal mounting and data collection for protein crystallography. Struct. Fold. Des. 2000, 8, R243-R246.
36. Nienaber, V.L.; Richardson, P.L.; Klighofer, V.; Bouska, J.J.; Giranda, V.L.; Greer, J. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol., 2000, 18, 1105-1108.
37. Perspicace, S.; Banner, D.; Benz, J.; Müller, F.; Schlatter, D.; Huber, W. Fragment-based screening using surface plasmon resonance technology. J. Biomol. Screen., 2009, 14, 337-49.
38. Pantoliano M.W.; Salemme F.R.; Carver T.E. High throughput method for functionally classifying proteins identified using a genomics approach.U.S. Patent Application Serial No. US 2002/0168686 A1, published Nov.14, 2002.
39. Lo, M.C.; Aulabaugh, A.; Jin, G.; Cowling, R.; Bard, J.; Malamas, M.; Ellestad, G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 2004, 332, 153-159.
40. Cummings, M.D.; Farnum, M.A.; Nelen, M.I. Universal Screening Methods and Applications of ThermoFluor®. J. Biomol. Screen., 2006, 11, 854-863
41. Boettcher, A.; Ruedisser, S.; Erbel, P.; Vinzenz, D.; Schiering, N.; Hassiepen, U.; Rigollier, P.; Mayr, L.M.; Woelcke, J. Fragment- Based Screening by Biochemical Assays: Systematic Feasibility Studies with Trypsin and MMP12. J. Biomol. Screen., 2010, 15, 1029-1041.
42. Barker, J.; Courtney, S.; Hesterkamp, T.; Ullmann, D.; Whittaker, M. Fragment screening by biochemical assay. Expert Opin. Drug Discov., 2006, 1, 225-236.
43. Maly D.J.; Choong I.C.; Ellman J.A. Combinatorial target-guided ligand assembly: identification of potent subtype-selective s-Src inhibitors. PNAS, 2009, 7, 2419-2424.
44. Matthews, T.P.; Klair, S.; Burns, S.; Boxall, K.; Cherry, M.; Fisher, M.; Westwood, I.M.; Walton, M.I.; McHardy, T.; Cheung, K-M. J.; Van Montfort, R.; Williams, D.; Aherne, G.W.; Garrett, M.D.; Reader, J.; Collins, I. Identification of Inhibitors of Checkpoint Kinase 1 through Template Screening. J. Med. Chem., 2009, 52, 4810-4819
45. Barker, J.J.; Barker, O.; Boggio, R.; Chauhan, V.; Cheng, R.K.Y.; Corden, V.; Courtney, S.M.; Edwards, N.; Falque, V.M.; Fusar, F. Gardiner, M.; Hamelin, E.M.N.; Hesterkamp, T.; Ichihara, O.; Jones, R.S.; Mather, O.; Mercurio, C.; Minucci, S.; Montalbetti, C.A.G.N.; Müller, A.; Patel, D.; Phillips, B.G.; Varasi, M.; Whittaker, M.; Winkler, D.; Yarnold, C.J. Fragment-based identification of HSP90 inhibitors. Chem. Med. Chem., 2009, 4, 963-966.
46. The PyMOL Molecular Graphics System, Schrödinger, LLC.
47. Howard, S.; Berdini, V.; Boulstridge, J.A.; Carr, M.G.; Cross, D.M.; Curry, J.; Devine, L.A.; Early, T.R.; Fazal, L.; Gill, A.L.; Heathcote, M.; Maman, S.; Matthews, J.E.; McMenamin, R.L.; Navarro, E.F.; O'Brien, M.A.; O'Reilly, M.; Rees, D.C.; Reule, M.; Tisi, D.; Williams, G.; Vinković, M.; Wyatt, P.G. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a ultitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. J. Med. Chem., 2009, 52, 379-388.
48. Mora, A.; Komander, D.; van Aalten, D.M.; Alessi, D.R. PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol., 2004, 15(2), 161-70.
49. Medina, J.R.; Blackledge, C.W.; Heerding, D.A.; Campobasso, N.; Ward, P.; Briand, J.; Wright, L.; Axten, J.M. Aminoindazole PDK1 inhibitors: a case study in fragment-based drug discovery. ACS Med. Chem. Lett., 2010, 1, 439-442.
50. Potter A.J.; Ray S.; Gueritz L.; Nunns C.L.; Bryant C.J.; Scrace S.F.; Matassova N.; Baker L.; Dokurno P.; Robinson D.A.; Surgenor A.E.; Davis B.; Murray J.B.; Richardson C.M.; Moore J.D. Structure-guided design of alpha-amino acid-derived Pin1 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 586-90.
51. Petros A.M.; Huth J.R.; Oost T.; Park C.M.; Ding H.; Wang X.; Zhang H.; Nimmer P.; Mendoza R.; Sun C.; Mack J.; Walter K.; Dorwin S.; Gramling E.; Ladror U.; Rosenberg S.H.; Elmore S.W.; Fesik S.W.; Hajduk P.J. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg. Med. Chem. Lett., 2010, 20, 6587-6591.
52. Tse, C.; Shoemaker, A.R.; Adickes, J.; Anderson, M.G.; Chen, J.; Jin, S.; Johnson, E.F.; Marsh, K.C.; Mitten, M.J.; Nimmer, P.; Roberts, L.; Tahir, S.K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S.H.; Elmore, S.W. ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. Cancer Res, 2008, 68, 3421-3428.
53. Gandhi, L.; Camidge, D.R.; de Oliveira, M.R.; Bonomi, P.; Gandara, D.; Khaira, D.; Hann, C.L.; McKeegan, E.M.; Litvinovich, E.; Hemken, P.M.; Dive, C.; Enschede, S.H.; Nolan, C.; Chiu, Y-L.; Busman, T.; Xiong, H.; Krivoshik, A.P.; Humerickhouse, R.; Shapiro, G.I.; Rudin, C.M. Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. J Clin Oncol., 2011, 29, 909-916.
54. Hubbard, R.E. Fragment approaches in structure-based drug discovery. J. Synchrotron Rad., 2008, 15, 227-230.
55. Cheung, K. M.; Matthews, T. P.; James, K.; Rowlands, M. G.; Boxall, K. J.; Sharp, S. Y.; Maloney, A.; Roe, S. M.; Prodromou, C.; Pearl, L. H.; Aherne, G. W.; McDonald, E.; Workman, P. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrzole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 3338-3343.
56. Sharp, S.Y.; Prodromou, C.; Boxall, K.; Powers, M.V.; Holmes, J.L.; Box, G.; Matthews, T.P.; Cheung, K.M.; Kalusa, A.; James, K.; Hayes, A.; Hardcastle, A.; Dymock, B.; Brough, P.A.; Barril, X.; Cansfield, J.E.; Wright, L.; Surgenor, A.; Foloppe, N.; Hubbard, R.E.; Aherne, W.; Pearl, L.; Jones, K.; McDonald, E.; Raynaud, F.; Eccles, S.; Drysdale, M.; Workman, P. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol. Cancer Ther., 2007, 6, 1198-1211.
57. Caldwell, J.J.; Davies, T.G.; Donald, A.; McHardy, T.; Rowlands, M.G.; Aherne, G.W.; Hunter, L.K.; Taylor, K.; Ruddle, R.; Raynaud, F.I.; Verdonk, M.; Workman, P.; Garrett, M.D.; Collins, I. Identification of 4-(4-Aminopiperidin-1-yl)-7H-pyrrolo[2,3- d]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration. J. Med. Chem., 2008, 51 (7), 2147-2157.
58. Wyatt, P.G.; Woodhead, A.J.; Berdini, V.; Boulstridge, J.A.; Carr, M.G.; Cross, D.M.; Davis, D.J.; Devine, L.A.; Early, T.R.; Feltell, R.E.; Lewis, E.J.; McMenamin, R.L.; Navarro, E.F.; O'Brien, M.A.; O'Reilly, M.; Reule, M.; Saxty, G.; Seavers, L.C.; Smith, D.M.; Squires, M.S.; Trewartha, G.; Walker, M.T.; Woolford, A.J. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)- 1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J. Med. Chem., 2008, 51, 4986-4999.
59. Frederickson, M.; Callaghan, O.; Chessari, G.; Congreve, M.; Cowan, S.R.; Matthews, J.E.; McMenamin, R.; Smith, D.; Vinkovi, M.; Wallis, N.G. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J. Med. Chem., 2008, 51, 183-186.
60. Tsai, J.; Lee, J.T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N.K.; Sproesser, K.; Li, L.; Smalley, K.S.M.; Fong, D.; Zhu, Y.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S.; Schlessinger, J.; Zhang, K.Y.J.; West, B.L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P.N.; Hirth, P.; Artis, D.R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. In Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3041-3046.
61. Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P.N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E.A.; Wong, B.; Tsang, G.; West, B.L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K.Y.J.; Artis, D.R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; D'Andrea, K.; Koehler, A.; Stumm, M.; Lin, P.S.; Lee, R.J.; Grippo, J.; Puzanov, I.; Kim, K.B.; Ribas, A.; McArthur, G.A.; Sosman, J.A.; Chapman, P.B.; Flaherty, K.T.; Xu, X.; Nathanson, K.L.; Nolop, K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467, 596-599.
62. Plexxikon Inc. Press Releases. http://www.plexxikon.com/view.cfm/86/Press-Releases (Accessed May 16, 2011).
63. Reich, S. Fragment-based Lead Discovery Conference, San Diego, CA, USA, 2008.
64. O'Hare, T.; Eide, C.A.; Tyner, J.W.; Corbin, A.S.; Wong, M.J.; Buchanan, S.; Holme, K.; Jessen, K.A.; Tang, C.; Lewis, H.A.; Romero, R.D.; Burley, S.K.; Deininger, M.W. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. PNAS, 2008, 105, 5507-5512.
65. Reader, J.; Williams, D.; Klair, S.; Cherry, M.; Fisher, M.; Scanlon, J.; Piton, N.; Addison, G.; Lamers, M.; Tall, M.; Proisy, N.; Cheung, K-M.; McHardy, T.; Matthews, T.; Hayes, A.; Boxall, K.; Burns, S.; Eve, P.; Walton, M.I.; Raynaud, F.; Aherne, G.W.; Workman, P.; Garrett, M.D.; Collins, I. Identification and Structure- guided Optimisation of Novel Inhibitors of Checkpoint Kinase 1 (Chk1) through Combined Biochemical and Crystallographic Screening. AACR Annual Meeting, San Diego, CA, Apr 12-16, 2008
66. Matthews, T.P.; Klair, S.; Burns, S.; Boxall, K.; Cherry, M.; Fisher, M.; Westwood, I.M.; Walton, M.I.; McHardy, T.; Cheung, K-M.J.; Van Montfort, R.; Williams, D.; Aherne, G.W.; Garrett, M.D.; Reader, J.; Collins, I. Identification of inhibitors of checkpoint kinase 1 through template screening. J. Med. Chem., 2009, 52, 4810-4819.
67. Antonysamy, S.; Hirst, G.; Park, F.; Sprengeler, P.; Stappenbeck, F.; Steensma, R.; Wilson, M.; Wong, M. Fragment-based discovery of JAK-2 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 279-282.